• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ALLERGAN (PRINGY) JUVEDERM VOLUMA XC/LIDO (VOLUME UNKNOWN); IMPLANT, DERMAL, FOR AESTHETIC USE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ALLERGAN (PRINGY) JUVEDERM VOLUMA XC/LIDO (VOLUME UNKNOWN); IMPLANT, DERMAL, FOR AESTHETIC USE Back to Search Results
Catalog Number UNK JUVEDERM VOLUMA XC/LIDO
Device Problem Off-Label Use (1494)
Patient Problem Nodule (4551)
Event Date 01/15/2022
Event Type  Injury  
Manufacturer Narrative
Further information from the reporter regarding event, product, or patient details has been requested.No additional information is available at this time.The events are physiological complications and analysis of the device generally does not assist allergan in determining a probable cause for these events.The filler was injected into the patient and is not accessible for return.The syringe was discarded.This is a known potential adverse event addressed in the product labeling.
 
Event Description
Healthcare professional reported injecting a patient in the tear trough with 1 ml of juvéderm® voluma¿ xc.A year later, the patient received their first covid-19 vaccines and the second one a month later.A month after the 2nd vaccine, the patient was injected in the lips with 1 syringe of juvéderm® volbella¿ xc and in the cheeks with 2 syringes of juvéderm® voluma¿ xc.Approximately two months later, the patient experienced ¿swelling, induration and nodules," "latent hypersensitivity reaction," "red, swollen nodules noted under in right tear trough" and "hard to the touch and swollen" lips.The patient self-treated with benadryl.Two months later, the patient visited the office and was given a tapered steroid dose, 3 (20 mg) tabs for 2 days, 2 (20 mg) tabs for 2 days, and 1 (20 mg) tab for 3 days.When treatment ended, the event resumed.The event is ongoing.This is the same event and the same patient reported under mdr id# 3005113652-2022-00182 (allergan complaint # (b)(4)) and mdr id# 3005113652-2022-00183 (allergan complaint # (b)(4)).This mdr is being submitted for the first injection of suspect product, juvéderm® voluma¿ xc.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
JUVEDERM VOLUMA XC/LIDO (VOLUME UNKNOWN)
Type of Device
IMPLANT, DERMAL, FOR AESTHETIC USE
Manufacturer (Section D)
ALLERGAN (PRINGY)
route de promery
zone artisanale de pre-mairy
pringy
Manufacturer (Section G)
ALLERGAN (PRINGY)
route de promery
zone artisanale de pre-mairy
pringy
Manufacturer Contact
chris sprague
12331-a riata trace parkway
building 3
austin, TX 78727
8479375615
MDR Report Key13931306
MDR Text Key291239221
Report Number3005113652-2022-00181
Device Sequence Number1
Product Code LMH
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P110033
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional,Company Representative
Reporter Occupation Nurse
Type of Report Initial
Report Date 03/28/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/28/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue NumberUNK JUVEDERM VOLUMA XC/LIDO
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received03/16/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other; Required Intervention;
Patient Age51 YR
Patient SexFemale
-
-